BRIEF-Fusion Pharmaceuticals Announces FDA Clearance Of Ind For Fpi-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing Fgfr3

reuters.com ยท 2021-07-28 16:59
BRIEF-Fusion Pharmaceuticals Announces FDA Clearance Of Ind For Fpi-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing Fgfr3

July 28 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O:

  • FUSION PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR FPI-1966, AN INVESTIGATIONAL RADIOPHARMACEUTICAL FOR THE TREATMENT OF HEAD AND NECK AND BLADDER CANCERS EXPRESSING FGFR3

  • FUSION - PLANS TO INITIATE PHASE 1, NON-RANDOMIZED, OPEN-LABEL CLINICAL TRIAL IN PATIENTS WITH SOLID TUMORS EXPRESSING FGFR3

Source text for Eikon: ID:nPn5BmWXfa

Further company coverage: FUSN.O


((Reuters.Briefs@thomsonreuters.com;))